According to the Africa News page, Dolutegravir (DTG) was first approved in 2013 in the United States for people who had never taken antiretroviral therapy.
Sub-Saharan Africa has been the epicenter of the lethal epidemic of human immunodeficiency virus (HIV) for decades, and currently, about three-quarters of all the people affected by the disease live in this area of the world.
The purpose of UNAIDS is that 90 percent of those diagnosed with HIV receive antiretroviral drugs by 2020.
Kenya, with one of the world’s largest HIV-positive populations, has made significant progress in treating the disease at its public health facilities, according to press reports. Continue reading